Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2022-09-30 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders (临时股东大会) for the company 普莱柯生物工程股份有限公司. It includes details about the meeting date, voting methods, agenda items, and instructions for shareholders to register and vote. It does not contain financial statements or detailed financial analysis, nor is it a transcript or report of the meeting results. It is a formal announcement to shareholders about the upcoming meeting and how to participate. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-09-30 Chinese
华泰联合证券有限责任公司关于普莱柯生物工程股份有限公司使用部分闲置募集资金及自有资金进行现金管理的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a securities company (华泰联合证券有限责任公司) regarding the use of idle raised funds and self-owned funds by 普莱柯生物工程股份有限公司 for cash management. It includes specifics about the amount of funds, investment purposes, decision-making processes, approvals by the board, independent directors, and supervisory board, as well as compliance with regulatory requirements. The document is not a brief announcement but a comprehensive statement about the company's financial management activities related to fundraising and cash management. It does not contain quarterly or annual financial statements, nor is it a transcript or presentation. It is a regulatory compliance and financial management report related to capital use and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4032 characters, which is substantial and contains detailed information rather than a simple announcement or certification.
2022-09-30 Chinese
普莱柯独立董事关于第四届董事会第三十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a specific board meeting matter regarding the use of idle raised funds and company funds for cash management. It references compliance with company law, securities law, and stock exchange listing rules. The content is about approval and opinion on financial management decisions, not a full financial report or earnings release. The document length is short (599 characters) and it is a formal opinion related to board/management decisions. This fits best under Board/Management Information (MANG) as it concerns board meeting matters and independent director opinions on company financial management actions.
2022-09-30 Chinese
普莱柯关于使用部分闲置募集资金及自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the use of idle raised funds and own funds for cash management. It details the investment types, amounts, decision-making process, risk control measures, and approvals by the board, supervisory committee, and independent directors. The document is a formal disclosure about financing and capital management activities, specifically about using idle funds for short-term financial products. It is not a full financial report, audit report, or earnings release. It is not a notice of dividend, voting results, or management change. The document is a capital/financing update about the company's use of funds and investment decisions. The length is about 4,000 characters, which is consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-09-30 Chinese
普莱柯第四届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed at the 17th meeting of the 4th Supervisory Board of 普莱柯生物工程股份有限公司. It details the meeting date, attendance, and the approval of a proposal regarding the use of idle raised funds and company funds for cash management. The document states that the proposal will be submitted to the shareholders' meeting for approval. The content is a formal announcement of a board or supervisory committee decision rather than a full report or financial statement. It does not contain financial statements or detailed financial analysis, nor is it a call transcript or an earnings release. It is not a report publication announcement or a regulatory filing in the general sense but a specific board/management information announcement about internal governance decisions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on a board resolution, consistent with MANG filings.
2022-09-30 Chinese
普莱柯关于持股5%以上股东集中竞价减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from a company disclosing a planned share reduction by a shareholder holding more than 5% of the company's shares. It details the shareholder's current holdings, the planned amount and timing of the share reduction, the reasons for the reduction, and compliance with relevant securities laws and regulations. The document does not contain financial statements, earnings data, or management discussion but focuses on the shareholder's transaction plan and regulatory compliance. This fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels.
2022-09-26 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.